Main page content

Displaying results 1 - 10 of 13
Publication ID: PEP23-02-01-002
Published:

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

Publication ID: PEP23-02-00-004
Published:

This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.

Publication ID: PEP23-02-00-001
Published:

The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.

Publication ID: PEP22-01-02-001
Published:

The National Guidelines for Child and Youth Behavioral Health Crisis Care offers best practices, implementation strategies, and practical guidance for the design and development of services that meet the needs of children, youth, and their families experiencing a behavioral health crisis. Additional technical guidance is provided in a companion report produced by SAMHSA in conjunction with the National Association of State Mental Health Program Directors, A Safe Place to Be: Crisis Stabilization Services and Other Supports for Children and Youth.

Publication ID: PEP21-05-00-002
Published:

There are protections in federal law, collectively known as “parity,” which are designed to ensure that certain types of health plans cover mental and substance use disorders no less generously than they cover other health issues. This resource can guide you to helpful materials and places.

Publication ID: PEP21-06-01-003
Published:

This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

Publication ID: PEP21-02-01-002
Published:

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Publication ID: PEP21-03-00-001
Published:

Alcohol remains the number one substance used by young people. These 24 legal policy summaries allow you to track how your state regulates underage drinking as compared to other states in order to help inform your prevention work.

Publication ID: SMA19-5094-PO
Published:

This poster is for clients and their family members in OUD treatment who are pregnant or who are currently not pregnant but of childbearing age.

Publication ID: SMA19-5094-FS
Published:

This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder

Displaying 1 - 10 out of 13